68Ga-PSMA PET in the Renal Cell Carcinoma

Air Force Military Medical University of People's Liberation Army

Status

Enrolling

Conditions

PSMA PET

Metastases

Renal Cancer

Treatments

Diagnostic Test: PSMA PET

Study type

Interventional

Funder types

Other

Identifiers

NCT04987086

KY20212033-F-1

Details and patient eligibility

About

The primary research purpose is to evaluate the diagnostic efficacy of 68Ga-PSMA PET in metastatic lesions of locally advanced and advanced renal cell carcinoma, and to compare with that of enhanced CT. The second purpose is to evaluate whether 68Ga-PSMA PET can change the treatment decision of patients with locally advanced and advanced renal cell carcinoma

Enrollment

300 estimated patients

Sex

All

Ages

18 to 90 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

2017 AJCC renal cell carcinoma TNM stage III, IV lesions;
In contrast-enhanced CT staging, suspicious metastases were found;
There were no known peripheral or central venous problems;
68Ga PSMA PET / CT imaging can be performed within 6 weeks after the diagnosis of renal cell carcinoma;
Signed the informed consent form of voluntary participation in clinical trials.

Exclusion criteria

Age ≤ 18 years old;
Can't stand lying flat in PET / CT examination;
There are contraindications for 68Ga PSMA ligands;
In the past two years, there was a history of other malignant tumors, or according to the doctor's research judgment, complications may occur and affect the normal operation of the test;
Renal function is impaired or hemodialysis is in progress.